Clinical Trial Update: REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A first-in-human study of RLY-4008, a highly selective FGFR2 inhibitor, in intrahepatic cholangiocarcinoma and other advanced solid tumors has completed Phase 1…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• RLY-4008

Snippet

Sponsor: Elevar Therapeutics | Conditions: FGFR2 Amplification, FGFR2 Gene Mutation | Phase 1, Phase 2 | Status: COMPLETED